Lotus Pharmaceutical Co., Ltd.
美時化學製藥股份有限公司
Lotus Pharmaceutical Co., Ltd. is a Taiwan TWSE-listed biotechnology company; its most advanced asset is Nintedanib (Commercialized), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| Nintedanib | — | Commercialized | — | North America, Europe, Taiwan | 2026-05-04 | Company disclosure |
| AVT34 (durvalumab biosimilar candidate) | — | Licensed development candidate; clinical phase not stated | — | United States, South Korea, Taiwan, Thailand, Vietnam, Philippines, Singapore, Hong Kong, Malaysia | 2026-08-21 | Company disclosure |
| AVT87 (emicizumab biosimilar candidate) | — | Licensed development candidate; clinical phase not stated | — | United States, South Korea, Taiwan, Thailand, Vietnam, Philippines, Singapore, Hong Kong, Malaysia | 2026-08-21 | Company disclosure |
Key events
- AVT34 and AVT87 biosimilar-candidate licensing and commercialization agreement
- Global Nintedanib soft-gel capsule launch
- Worldwide SLX-100 development and commercialization license